Pfizer reached an amended agreement to acquire obesity drug developer Metsera in a deal valued at about $10 billion, ending a week‑long bidding contest with Novo Nordisk. Pfizer’s offer matched its rival’s final bid and prompted Novo to confirm it would not increase its price. The acquisition brings Metsera’s GLP‑1 and amylin assets into Pfizer’s metabolic portfolio and accelerates the company’s push into obesity therapeutics.